close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

55.95 +0.63 (+1.14%)
Delayed Quote Updated: 2:57 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 617,673
Open 55.45
Bid (Size) 55.92 (100)
Ask (Size) 55.98 (200)
Prev. Close 55.32
Today's Range 54.82 - 56.59
52wk Range 44.12 - 78.48
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them? ↗
The company will be judged by the results of its peers, and it might not compare as well as shareholders hope. 
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles. 
Via The Motley Fool

Performance

YTD
+4.1%
+4.1%
1 Month
-1.8%
-1.8%
3 Month
+0.6%
+0.6%
6 Month
+14.6%
+14.6%
1 Year
-13.7%
-13.7%

More News

Read More
News headline image
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026 ↗
Via The Motley Fool
News headline image
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics Eyes CASGEVY Growth, Year-End Pipeline Catalysts ↗
Via MarketBeat
Topics Intellectual Property
News headline image
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September ↗
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Rocked the Market Last Month ↗
Via The Motley Fool
News headline image
Where Will CRISPR Therapeutics Stock Be in 5 Years? ↗
Via The Motley Fool
News headline image
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? ↗
Via The Motley Fool
Topics ETFs Stocks
News headline image
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗
Via The Motley Fool
News headline image
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? ↗
Via The Motley Fool
News headline image
3 Stocks With the Most Upside by the End of 2026 ↗
Via The Motley Fool
Topics Workforce
News headline image
3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside ↗
Via The Motley Fool
News headline image
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating ↗
Via The Motley Fool
Topics ETFs
News headline image
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? ↗
Via The Motley Fool
News headline image
3 Reasons to Buy CRISPR Therapeutics Stock ↗
Via The Motley Fool
News headline image
Vertex’s Crinetics Deal Balances Growth with Integration Risk ↗
Via MarketBeat
News headline image
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗
Via The Motley Fool
News headline image
Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool

Frequently Asked Questions

Is CRISPR Therapeutics AG - Common Shares publicly traded?
Yes, CRISPR Therapeutics AG - Common Shares is publicly traded.
What exchange does CRISPR Therapeutics AG - Common Shares trade on?
CRISPR Therapeutics AG - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for CRISPR Therapeutics AG - Common Shares?
The ticker symbol for CRISPR Therapeutics AG - Common Shares is CRSP on the Nasdaq Stock Market
What is the current price of CRISPR Therapeutics AG - Common Shares?
The current price of CRISPR Therapeutics AG - Common Shares is 55.95
When was CRISPR Therapeutics AG - Common Shares last traded?
The last trade of CRISPR Therapeutics AG - Common Shares was at 10/01/26 02:57 PM ET
What is the market capitalization of CRISPR Therapeutics AG - Common Shares?
The market capitalization of CRISPR Therapeutics AG - Common Shares is 4.42B
How many shares of CRISPR Therapeutics AG - Common Shares are outstanding?
CRISPR Therapeutics AG - Common Shares has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.